Zacks: Analysts Anticipate Shire PLC (SHPG) to Announce $3.90 EPS
Equities analysts expect that Shire PLC (NASDAQ:SHPG) will post earnings of $3.90 per share for the current quarter, Zacks reports. Four analysts have made estimates for Shire PLC’s earnings, with estimates ranging from $3.72 to $4.01. Shire PLC posted earnings per share of $3.37 in the same quarter last year, which indicates a positive year-over-year growth rate of 15.7%. The firm is expected to announce its next earnings report on Thursday, February 15th.
According to Zacks, analysts expect that Shire PLC will report full year earnings of $15.00 per share for the current fiscal year, with EPS estimates ranging from $14.78 to $15.16. For the next fiscal year, analysts forecast that the firm will post earnings of $16.06 per share, with EPS estimates ranging from $15.31 to $16.80. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Shire PLC.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.64 by $0.17. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The business had revenue of $3.70 billion during the quarter. During the same period in the previous year, the firm posted $3.17 earnings per share. The company’s quarterly revenue was up 7.1% compared to the same quarter last year.
A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 price objective on shares of Shire PLC in a research note on Wednesday, July 12th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $222.00 price objective on shares of Shire PLC in a research note on Thursday, September 14th. BidaskClub cut Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $160.00 price objective on shares of Shire PLC in a research note on Friday, October 27th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $210.00 price objective on shares of Shire PLC in a research note on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $211.00.
Shares of Shire PLC (NASDAQ:SHPG) traded up $0.77 during midday trading on Friday, hitting $146.52. The stock had a trading volume of 308,920 shares, compared to its average volume of 1,200,501. The firm has a market capitalization of $43,677.09, a price-to-earnings ratio of 10.00 and a beta of 1.60.
The firm also recently disclosed a semiannual dividend, which was paid on Friday, October 20th. Stockholders of record on Friday, September 8th were given a dividend of $0.1527 per share. The ex-dividend date was Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio is currently 17.23%.
Large investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its position in shares of Shire PLC by 2.9% during the 3rd quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock worth $8,793,000 after acquiring an additional 1,619 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of Shire PLC by 63.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock worth $2,941,000 after acquiring an additional 6,917 shares in the last quarter. Baldwin Investment Management LLC boosted its position in shares of Shire PLC by 1.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after acquiring an additional 23 shares in the last quarter. Oak Ridge Investments LLC lifted its holdings in shares of Shire PLC by 3.2% in the 2nd quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock valued at $13,389,000 after purchasing an additional 2,528 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its holdings in shares of Shire PLC by 38.8% in the 2nd quarter. Federated Investors Inc. PA now owns 9,153 shares of the biopharmaceutical company’s stock valued at $1,513,000 after purchasing an additional 2,560 shares during the last quarter. 19.27% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/zacks-analysts-anticipate-shire-plc-shpg-to-announce-3-90-eps.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.